CSBR Champions Oncology

Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computational-based discovery platforms, unique oncology software solutions, and innovative and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms.

Company profile

Ronnie Morris
Fiscal year end
Former names
IRS number

CSBR stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


26 Jul 21
2 Aug 21
30 Apr 22
Quarter (USD)
Apr 21 Jan 21 Oct 20 Jul 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Apr 21 Apr 20 Apr 19 Apr 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 4.69M 4.69M 4.69M 4.69M 4.69M 4.69M
Cash burn (monthly) 914K 304.58K 216K (positive/no burn) 660K 140.08K
Cash used (since last report) 2.85M 949.66K 673.47K n/a 2.06M 436.77K
Cash remaining 1.84M 3.74M 4.01M n/a 2.63M 4.25M
Runway (months of cash) 2.0 12.3 18.6 n/a 4.0 30.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
23 Mar 21 Philip P. Breitfeld Common Stock Payment of exercise Dispose F No No 11.35 1,340 15.21K 2,827
23 Mar 21 Philip P. Breitfeld Common Stock Option exercise Aquire M No No 3.65 4,167 15.21K 4,167
23 Mar 21 Philip P. Breitfeld Option to purchase Common Stock Common Stock Option exercise Dispose M No No 3.65 4,167 15.21K 0
19 Jan 21 Abba David Poliakoff Common Stock Payment of exercise Aquire F No No 11.53 8,873 102.31K 81,274
19 Jan 21 Abba David Poliakoff Common Stock Option exercise Aquire M No No 5.43 10,000 54.3K 90,147
19 Jan 21 Abba David Poliakoff Common Stock Option exercise Aquire M No No 3.21 10,000 32.1K 80,147
19 Jan 21 Abba David Poliakoff Common Stock Option exercise Aquire M No No 1.59 10,000 15.9K 70,147
19 Jan 21 Abba David Poliakoff Option to purchase Common Stock Common Stock Option exercise Dispose M No No 5.43 10,000 54.3K 0
19 Jan 21 Abba David Poliakoff Option to purchase Common Stock Common Stock Option exercise Dispose M No No 3.21 10,000 32.1K 0
19 Jan 21 Abba David Poliakoff Option to purchase Common Stock Common Stock Option exercise Dispose M No No 1.59 10,000 15.9K 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

53.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 45 47 -4.3%
Opened positions 1 6 -83.3%
Closed positions 3 5 -40.0%
Increased positions 19 12 +58.3%
Reduced positions 15 19 -21.1%
13F shares
Current Prev Q Change
Total value 90.11M 87.35M +3.2%
Total shares 7.2M 7.13M +1.0%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Battery Management 2.42M $27.37M 0.0%
NEA Management 1.71M $19.37M 0.0%
BLK Blackrock 470.45K $5.32M +1.1%
Vanguard 464.54K $5.25M +7.5%
Roubaix Capital 279.3K $3.16M +35.3%
Millrace Asset 260.08K $2.94M +42.6%
Tocqueville Asset Management 252.46K $2.85M 0.0%
Renaissance Technologies 228.43K $2.58M +3.0%
Dimensional Fund Advisors 128.29K $1.45M -2.4%
STT State Street 101.46K $1.15M +6.1%
Largest transactions
Shares Bought/sold Change
EAM Investors 0 -99.76K EXIT
Millrace Asset 260.08K +77.75K +42.6%
Roubaix Capital 279.3K +72.8K +35.3%
WFC Wells Fargo & Co. 53.78K +43.45K +420.5%
Vanguard 464.54K +32.37K +7.5%
Zebra Capital Management 0 -32.08K EXIT
BMO Bank of Montreal 74.01K -21.82K -22.8%
NTRS Northern Trust 88.94K -18.32K -17.1%
Renaissance Technologies 228.43K +6.69K +3.0%
Ingalls & Snyder 11.06K -6K -35.2%

Financial report summary

Vyant Bio
  • We historically incurred losses from operating activities, may require significant capital and may never achieve sustained profitability.
  • We may incur greater costs than anticipated, which could result in sustained losses.
  • We may not be able to implement our business strategies which could impair our ability to continue operations.
  • Our business could be adversely impacted by changes in FDA’s regulatory oversight of laboratory-developed tests such as our POS services that are currently under consideration or by other changes in the regulatory requirements applicable to our POS services imposed by the FDA or regulatory authorities in other countries in which our services are provided.
  • Our laboratories are subject to regulation and licensure requirements, and the healthcare industry is highly regulated; we may face substantial penalties, and our business activities may be impacted, if we fail to comply.
  • If our laboratory facilities are damaged or destroyed, or we have a dispute with one of our landlords, our business would be negatively affected.
  • Any health crisis impacting our colony of laboratory mice could have a negative impact on our business.
  • We have limited experience marketing and selling our products and may need to rely on third parties to successfully market and sell our products and generate revenues.
  • We will continue to be dependent upon key employees.
  • Because our industry is very competitive and many of our competitors have substantially greater capital resources and more experience in research and development, we may not succeed in selling or increasing sales of our products and technologies.
  • If we are unable to protect our intellectual property, we may not be able to compete as effectively.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Claims by others that our products infringe their patents or other intellectual property rights could adversely affect our financial condition.
  • Patients are unable to obtain reimbursement from third-party payers for our services, limiting the market acceptance of our services, and as a result we may not achieve significant revenues.
  • Research service studies are subject to cancellation based on changes in customer’s development plans.
  • We face competition in the life science market for computational software and for bioinformatics products.
  • Our ability to use our net operating loss carry-forwards and certain other tax attributes may be limited.
  • We have a limited market for our common stock, which makes our securities very speculative.
  • Investment in our common stock may be diluted if we issue additional shares in the future.
  • Our stock price is volatile and therefore investors may not be able to sell their common stock at or above the price they paid for it.
  • Certain provisions of our charter and bylaws and of our contractual agreements contain provisions that could delay and discourage takeover attempts and any attempts to replace our current management by stockholders.
  • Our management and three significant stockholders collectively own a substantial majority of our common stock.
  • We have not paid any cash dividends in the past and have no plans to issue cash dividends in the future, which could cause the value of our common stock to have a lower value than other similar companies which do pay cash dividends.
  • If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the price of our common stock and trading volume could decline.
  • A pandemic, epidemic, or outbreak of an infectious disease in the United States or elsewhere may adversely affect our business and we are unable to predict the potential impact.
Content analysis
H.S. freshman Avg
New words: academia, accessed, adapt, alter, analytical, antidilutive, artificial, Asia, augment, barrier, begun, biomarker, biopharmaceutical, biopsy, career, center, centered, characteristic, constantly, correct, corrected, correction, coupled, crucial, Cultivating, culture, curation, cytometry, datacenter, dataset, deeper, deeply, deficiency, deployed, detail, detailed, developmental, diagnosed, diminished, eased, ecosystem, elegant, employ, engineering, enterprise, entry, environment, ethnicity, Europe, fact, feature, feel, foundation, GCLP, histology, hosting, Importantly, inadequate, innovation, innovative, insight, intelligence, judgement, layer, led, legacy, lifted, Lumin, matter, metastatic, minimal, missing, NaN, nascent, necessarily, network, Notwithstanding, pertain, pharmacologic, pharmacological, pharmacology, phenotypic, philosophy, pipeline, post, pre, precise, preeminent, pressured, prioritized, privacy, progressed, publicly, quickly, ready, released, remediate, remediated, remediation, remit, remuneration, repertoire, reputation, revised, rich, robust, safe, sector, segregated, society, solid, sophisticated, source, SOW, stemming, stream, strong, superior, talent, target, therapeutic, transformative, transforming, unauthorized, unsuccessful, usability, version, viable, Xenograft
Removed: abba, accomplish, analyzed, applying, billion, body, built, calling, chance, classification, Clopper, closed, collection, consumer, contemplated, COSO, database, DC, deducting, diversity, empirically, ensure, epigenetic, executing, extensive, facilitated, failure, Food, Gaithersburg, gathering, gene, highest, humanized, immune, inhibition, integrated, invested, lodging, metastic, mouse, mutational, opportunity, panel, paradigm, partial, path, permanent, phase, pioneer, poliakoff, populate, positive, predicting, preserved, representing, reviewed, Road, Room, run, scale, setting, shipping, shortening, simulate, simulated, simulating, simulation, spending, sponsored, Street, tracked, transition, treated, trial, underwriter, underwriting, vested, Washington